It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Alterations of RUNX1 in acute myeloid leukemia (AML) are associated with either a more favorable outcome in the case of the RUNX1/RUNX1T1 fusion or unfavorable prognosis in the case of point mutations. In this project we aimed to identify genes responsible for the observed differences in outcome that are common to both RUNX1 alterations. Analyzing four AML gene expression data sets (n = 1514), a total of 80 patients with RUNX1/RUNX1T1 and 156 patients with point mutations in RUNX1 were compared. Using the statistical tool of mediation analysis we identified the genes CD109, HOPX, and KIAA0125 as candidates for mediator genes. In an analysis of an independent validation cohort, KIAA0125 again showed a significant influence with respect to the impact of the RUNX1/RUNX1T1 fusion. While there were no significant results for the other two genes in this smaller validation cohort, the observed relations linked with mediation effects (i.e., those between alterations, gene expression and survival) were almost without exception as strong as in the main analysis. Our analysis demonstrates that mediation analysis is a powerful tool in the identification of regulative networks in AML subgroups and could be further used to characterize the influence of genetic alterations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Jurinovic, Vindi 1 ; Batcha, Aarif M N 2 ; Bamopoulos, Stefanos A 3 ; Rothenberg-Thurley, Maja 3 ; Amler, Susanne 4 ; Sauerland, Maria Cristina 4 ; Berdel, Wolfgang E 5 ; Wörmann, Bernhard J 6 ; Bohlander, Stefan K 7 ; Braess, Jan 8 ; Hiddemann, Wolfgang 9 ; Lehmann, Sören 10 ; Mareschal, Sylvain 11
; Spiekermann, Karsten 9 ; Metzeler, Klaus H 9 ; Herold, Tobias 9
; Boulesteix, Anne-Laure 1 1 Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany
2 Institute for Medical Information Processing, Biometry and Epidemiology, LMU Munich, Munich, Germany; German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany
3 Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
4 Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany
5 Department of Medicine A, Hematology and Oncology, University of Muenster, Muenster, Germany
6 German Society of Hematology and Oncology, Berlin, Germany
7 Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
8 Department of Oncology and Hematology, Hospital Barmherzige Brüder, Regensburg, Germany
9 German Cancer Consortium (DKTK), partner site Munich, Munich, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
10 Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden; Department of Medicine, Karolinska Institute, Stockholm, Sweden
11 Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden; Department of Biosciences and Nutrition, Karolinska Institute, Stockholm, Sweden




